

CSE Symbol: IME  
OTC PINK Symbol: IMEXF  
Frankfurt/Stuttgart Stock Exchanges: DPD2

NR-2016-IME-15

## IMAGIN MEDICAL APPROVES DEBT SETTLEMENT

*Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in the early detection of bladder cancer through endoscopes.*

---

Vancouver, B.C. and Boston, MA, August 22, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announces that it has agreed to settle \$160,000 in outstanding debt to a creditor through the issuance of 1,600,000 shares at a deemed value of \$0.10 per share. Shares issued in connection with the debt settlement will be subject to a four-month hold period.

Upon completion of the debt settlement, it is expected that there will be approximately 41,372,634 common shares issued and outstanding.

### ***About Imagin Medical***

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at [www.imaginmedical.com](http://www.imaginmedical.com).

### **ON BEHALF OF THE BOARD:**

*Jim Hutchens,*  
President & CEO

### **For further information, contact:**

Bill Galine, Investor Relations  
Telephone: (775) 737-3292  
Email: [billgaline@gmail.com](mailto:billgaline@gmail.com)

**CAUTIONARY DISCLAIMER STATEMENT:** *The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.*

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*